Healthcare
Xenetic Biosciences, Inc.(XBIO)
Live Price
Offline$2.80
-6.98% today
1Y Change
+11.68%
Window
Jun 23, 2025 → Jun 16, 2026
- Market Cap
- $10.00M
- Revenue Growth
- +19.0%
- EPS Growth
- +38.5%
- Dividend Yield
- 0.0%
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Xenetic Biosciences, Inc. (XBIO) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $2.80 and up 11.7% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of +19.0%, EPS growth of +38.5%, a dividend yield of 0.0%. What stands out right now is revenue +19.0%, EPS +38.5%, free cash flow +18.8% with operating margin -95.2% and ROIC -38.3%. Valuation is more restrained than many high-expectation growth names at price/sales 1.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines XBIO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+19.0% vs +7.6% peer median
Operating Margin
Below sector median
-95.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +19.0% and EPS at +38.5%, with operating margin around -95.2%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XBIO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
XBIO Max Drawdown
-80.50%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for XBIO and SPY.
Company Overview
Xenetic Biosciences, Inc.
NASDAQ Capital Market
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
- Leadership
- James F. Parslow
- IPO Date
- Jun 30, 2016
- Employees
- 2
- Street Address
- 40 Speen Street
- Mailing
- Framingham, MA, 01701
- Region
- Framingham, MA, US
- Reporting Currency
- USD
- Investor Line
- 781 778 7720
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- 1.0
- Price/Sales
- 1.7
- Price/Book
- 0.9
Growth
- Revenue
- +19.0%
- EPS
- +38.5%
- Free Cash Flow
- +18.8%
Profitability
- Gross Margin
- 100.0%
- Operating Margin
- -95.2%
- Net Margin
- -90.1%
- ROE
- -51.2%
- ROIC
- -38.3%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 8.32
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.